|Tested species reactivity||Human|
|Published species reactivity||Human, Not Applicable|
|Host / Isotype||Mouse / IgG1|
|Immunogen||Small cell lung carcinoma cell line H69.|
|Storage buffer||PBS, pH 7.4|
|Contains||15mM sodium azide|
|Storage Conditions||4° C, do not freeze|
|Tested Applications||Dilution *|
|Flow Cytometry (Flow)||1-3 ug/ml|
|Immunocytochemistry (ICC)||4 ug/ml|
|Immunohistochemistry (Frozen) (IHC (F))||5-10 ug/ml|
|Immunohistochemistry (Paraffin) (IHC (P))||5-10 ug/ml|
|Immunoprecipitation (IP)||1-2 ug/ml|
|Western Blot (WB)||1-4 ug/ml|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
This gene encodes a carcinoma-associated antigen and is a member of a family that includes at least two type I membrane proteins. This antigen is expressed on most normal epithelial cells and gastrointestinal carcinomas and functions as a homotypic calcium-independent cell adhesion molecule. The antigen is being used as a target for immunotherapy treatment of human carcinomas. Mutations in this gene result in congenital tufting enteropathy. [provided by RefSeq, Dec 2008]
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
Optimisation of immunofluorescence methods to determine MCT1 and MCT4 expression in circulating tumour cells.
MA1-10195 was used in western blot to develop an immunofluorescence method to assess MCT1 and MCT4 in circulating tumor cells and as them as biomarkers of AZD3965 in cancer patients
|Kershaw S,Cummings J,Morris K,Tugwood J,Dive C||BMC cancer (15:null)||2015|
Neuropilin-2 Is upregulated in lung cancer cells during TGF-ß1-induced epithelial-mesenchymal transition.
MA1-10195 was used in western blot to study TGF-beta1-driven lung cancer cell epithelial-to-mesenchymal transition and the role played by neuropilin-2
|Nasarre P,Gemmill RM,Potiron VA,Roche J,Lu X,Barón AE,Korch C,Garrett-Mayer E,Lagana A,Howe PH,Drabkin HA||Cancer research (73:7111)||2013|
Transient but not stable ZEB1 knockdown dramatically inhibits growth of malignant pleural mesothelioma cells.
MA1-10195 was used in western blot to study the role of ZEB1 in mediating the growth of malignant pleural mesothelioma cells
|Horio M,Sato M,Takeyama Y,Elshazley M,Yamashita R,Hase T,Yoshida K,Usami N,Yokoi K,Sekido Y,Kondo M,Toyokuni S,Gazdar AF,Minna JD,Hasegawa Y||Annals of surgical oncology (19 Suppl 3:S634)||2012|
New frontiers in circulating tumor cell analysis: A reference guide for biomolecular profiling toward translational clinical use.
MA1-10195 was used in immunocytochemistry to review the current state-of-the-art in circulating tumor cell profiling
|Becker TM,Caixeiro NJ,Lim SH,Tognela A,Kienzle N,Scott KF,Spring KJ,de Souza P||International journal of cancer (134:2523)||2014|
A pilot study to explore circulating tumour cells in pancreatic cancer as a novel biomarker.
MA1-10195 was used in immunocytochemistry and immunohistochemistry - paraffin section to investigate epithelial to mesenchymal transition during metastasis of pancreatic cancer
|Khoja L,Backen A,Sloane R,Menasce L,Ryder D,Krebs M,Board R,Clack G,Hughes A,Blackhall F,Valle JW,Dive C||British journal of cancer (106:508)||2012|
Multiple breast cancer cell-lines derived from a single tumor differ in their molecular characteristics and tumorigenic potential.
MA1-10195 was used in flow cytometry to study the different molecular phenotype and tumorigenicity of 5 breast cancer cell lines derived from a single patient
|Mosoyan G,Nagi C,Marukian S,Teixeira A,Simonian A,Resnick-Silverman L,DiFeo A,Johnston D,Reynolds SR,Roses DF,Mosoian A||PloS one (8:null)||2013|
Systematic analysis and validation of differential gene expression in ovarian serous adenocarcinomas and normal ovary.
MA1-10195 was used in immunohistochemistry to identify genes differentially expressed in ovaraian serous adenocarcinoma as compared to healthy ovarian tissue
|Bauerschlag D,Bräutigam K,Moll R,Sehouli J,Mustea A,Salehin D,Krajewska M,Reed JC,Maass N,Hampton GM,Meinhold-Heerlein I||Journal of cancer research and clinical oncology (139:347)||2013|
Heritable somatic methylation and inactivation of MSH2 in families with Lynch syndrome due to deletion of the 3' exons of TACSTD1.
MA1-10195 was used in immunohistochemistry to investigate Lynch syndrome with MSH2-deficient tumors
|Ligtenberg MJ,Kuiper RP,Chan TL,Goossens M,Hebeda KM,Voorendt M,Lee TY,Bodmer D,Hoenselaar E,Hendriks-Cornelissen SJ,Tsui WY,Kong CK,Brunner HG,van Kessel AG,Yuen ST,van Krieken JH,Leung SY,Hoogerbrugge N||Nature genetics (41:112)||2009|
Molecular and prognostic distinction between serous ovarian carcinomas of varying grade and malignant potential.
MA1-10195 was used in immunohistochemistry to distinguish low malignant potential serous ovarian carcinomas from invasive counterparts
|Meinhold-Heerlein I,Bauerschlag D,Hilpert F,Dimitrov P,Sapinoso LM,Orlowska-Volk M,Bauknecht T,Park TW,Jonat W,Jacobsen A,Sehouli J,Luttges J,Krajewski M,Krajewski S,Reed JC,Arnold N,Hampton GM||Oncogene (24:1053)||2005|
Gene expression patterns in ovarian carcinomas.
MA1-10195 was used in immunohistochemistry to study gene expression patterns in ovarian carcinomas using DNA microarrays
|Schaner ME,Ross DT,Ciaravino G,Sorlie T,Troyanskaya O,Diehn M,Wang YC,Duran GE,Sikic TL,Caldeira S,Skomedal H,Tu IP,Hernandez-Boussard T,Johnson SW,O'Dwyer PJ,Fero MJ,Kristensen GB,Borresen-Dale AL,Hastie T,Tibshirani R,van de Rijn M,Teng NN,Longacre TA,Botstein D,Brown PO,Sikic BI||Molecular biology of the cell (14:4376)||2003|